Accenture and Philips Latest Research Enables ALS Patients to Turn on Lights by Thinking

Royal Philips (NYSE: PHG; AEX: PHIA) and Accenture (NYSE: ACN) today announced that they have developed proof of concept software connecting a wearable display to Emotiv Insight Brainware that could ultimately give more independence to patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Affecting more than 400,000 people per year*, ALS, also known as Lou Gehrig’s Disease, impairs brain and spinal cord nerve cells, gradually diminishing voluntary muscle action. Late-stage patients often become totally paralyzed while retaining brain functions.
 
“This proof of concept exemplifies how people, devices, data and technology could be brought together quickly to connect beyond the hospital walls in a way that can potentially help improve the quality of life for patients, wherever they are in their journey,” said Jeroen Tas, CEO, Healthcare Informatics Solutions and Services for Philips. “Philips will continue to collaborate with innovative technology companies such as Accenture to explore new wearable and sensor solutions that change peoples’ lives and create a healthier future.”

How it works
When a wearable display and the Emotiv Insight Brainware, which scans EEG brainwaves, are connected to a tablet, users can issue brain commands to control Philips products including Philips Lifeline Medical Alert Service, Philips SmartTV (with TP Vision), and Philips Hue personal wireless lighting. The tablet also allows control of these products using eye and voice commands. In both cases, a person could communicate preconfigured messages, request medical assistance, and control TVs and lights. Accenture and Philips developed the software that enables the integration and interaction between these multiple technologies.

The conceptual Emotiv Insight Brainware from Philips. (LEDinside/Philips)

The proof of concept application demonstrates how existing technology could be used to transform the quality of life for ALS patients. When patients lose muscle control and eye tracking ability, they can still potentially operate the Philips suite of connected products in their home environment through brain commands. The Emotiv technology uses sensors to tune in to electric signals produced by the wearer’s brain to detect, in real-time, their thoughts, feelings and expressions. The wearable display provides visual feedback that allows the wearer to navigate through the application menu.
 

The conceptual device enables users to switch on lights by detecting brain waves, or in other words "thinking about it."  (LEDinside/Philips)

The Accenture Technology Labs in San Jose, California collaborated with the Philips Digital Accelerator Lab in the Netherlands to create the software to interact with the Emotiv Insight Brainware and the wearable display. Fjord, a design consultancy owned by Accenture Interactive, designed the display’s user interface.

 
“This proof of concept shows the potential of wearable technology in a powerful new way —helping people with serious diseases and mobility issues take back some control of their lives through digital innovation,” said Paul Daugherty, Accenture’s chief technology officer. “It is another demonstration of how Accenture and Philips, collaborating with other technology innovators, seek to improve the lives of people with healthcare challenges.”

Accenture and Philips team working on the concept of the Emotiv. (LEDinside/Philips)

“Empowering people with Lou Gehrig’s disease to live fuller lives is at the heart of the ALS Association’s mission,” said Ineke Zaal, spokesperson for Stichting ALS in The Netherlands. “We are tremendously excited about the potential for this proof of concept to give people with ALS greater independence and quality of life as we continue to actively search for a cure.”
 
For more information on the proof of concept application for controlling Philips connected technologies with brain commands, visit http://www.philips.com/braincommand 
 
and join the continuing conversation on LinkedIn with Philips Innovations in Health Group.

*Source:International Alliance of ALS/MND Associations

Disclaimers of Warranties
1. The website does not warrant the following:
1.1 The services from the website meets your requirement;
1.2 The accuracy, completeness, or timeliness of the service;
1.3 The accuracy, reliability of conclusions drawn from using the service;
1.4 The accuracy, completeness, or timeliness, or security of any information that you download from the website
2. The services provided by the website is intended for your reference only. The website shall be not be responsible for investment decisions, damages, or other losses resulting from use of the website or the information contained therein<
Proprietary Rights
You may not reproduce, modify, create derivative works from, display, perform, publish, distribute, disseminate, broadcast or circulate to any third party, any materials contained on the services without the express prior written consent of the website or its legal owner.

DURHAM, NC – November 12, 2024 –– Cree LED, a Penguin Solutions brand (Nasdaq: PENG), today announced the launch of its new CV28D LEDs with FusionBeam™ Technology, a groundbreaking advancement for the LED signage market... READ MORE

The new IR:6 thin-film infrared LED chip technology is available in 850nm, 940nm and new 920nm wavelength options First IR:6-based products are the OSLON® P1616 and OSLON® Black series, giving customers a drop-in replacement that o... READ MORE